The present invention relates to the treatment of Senile Dementia of the Alzheimers Type (SDAT) by administering to the patient and effective amount of a compound selected from the group consisting of: 1-alkyl, 2-acyl-glyceraldehyde-3-phosphate (G3P) 1-alkyl, 2-acyl-glycerol and 1-alkyl, 2-acyl-glycerylphosphatidylethanolamine (CGPE) or a pharmaceutically acceptable salt thereof.